MAP1LC3A and cancer: Identifying the occurrence of an autophagic block by simple tools, such as late-stage inhibitor co-treatment or GFP-RFP-LC3 expression [105], will enable the determination of whether a genetic or pharmacological intervention on tubulin-modifying enzymes will promote cancer cell death by the cell toxicity associated with autophagosome accumulation [149] and could be usefully applied in the identification of therapeutically promising molecules.